Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it
works compared to aldesleukin alone in treating patients with melanoma that has spread from
where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin
may stimulate a person's white blood cells to kill melanoma cells. Vaccines may make the body
build an immune response to kill tumor cells. It is not yet known whether combining
aldesleukin with vaccine therapy is more effective than aldesleukin alone in treating
melanoma.